Whole exome sequencing of lung cancer in Indian patients reveals driver genes and novel mutations with therapeutic potential
- 6 June 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (3) , 631-643
Abstract
Lung cancer remains a leading cause of cancer mortality in India, yet its genomic landscape remains understudied. To address this gap, we performed whole-exome sequencing (WES) on tumor and matched blood samples from 47 lung cancer patients [adenocarcinoma (ADC): 30; squamous cell carcinoma (SqCC): 10; and small cell lung cancer (SCLC): 7] to comprehensively analyze somatic mutations across all protein-coding genes. Our analysis revealed novel and recurrent alterations, with MUC4 being the most recurrently mutated gene, and TP53 emerging as the most frequently mutated across subtypes. Shared mutations included MUC4, MUC16, TP53, KMT2C, CDC27, and UBXN11, the latter not previously associated with lung cancer. ADC exhibited the highest mutational diversity, particularly in RTK/MAPK pathway genes (EGFR, KRAS, BRAF, ERBB2, PIK3CG). Notably, EGFR mutations were identified in 26.7% of ADC cases, including exon 19 deletions (5 cases), exon 21 missense mutations (2 cases), and exon 20 insertions (3 cases) and a novel EGFR exon 20 duplication (p.Ser768_Asp770dup). SqCC showed frequent mutations in KMT2D, ARID2, and FBXW7, suggesting a role for epigenetic dysregulation. One SqCC case harbored a rare EGFR p.Glu866Gly mutation. SCLC was enriched for TP53 (43%) and RB1 (14%) mutations, along with alterations in FAT4 and LRP1B. Importantly, therapeutically actionable mutations were identified in 91.5% patients, including those with NCCN-recommended (25.5%) and FDA-approved off-label drug targets (68.1%). These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients.Keywords
Funding Information
- Rajiv Gandhi University of Health Sciences (#17C001B)
This publication has 86 references indexed in Scilit:
- Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung CancersCancer Medicine, 2025
- KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibitionCancer Cell, 2022
- Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genesComputers in Biology and Medicine, 2022
- CD4 T cells target colorectal cancer antigens upregulated by oxaliplatinInternational Journal of Cancer, 2019
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistryMedicinal Research Reviews, 2018
- Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 CasesClinical Lung Cancer, 2017
- Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapySurgery Today, 2017
- Functional MUC4 suppress epithelial–mesenchymal transition in lung adenocarcinoma metastasisTumor Biology, 2013
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancerBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profilingInternational Journal of Cancer, 2005